z-logo
open-access-imgOpen Access
Participation of Neuropeptides and β-endorphin in Pathogenesis of Atopic Dermatitis. Evaluation of Levocetirizine Effectiveness upon Neuropeptides' Levels at Children with Atopic Dermatitis
Author(s) -
V A Revyakina,
A S Agaphonov,
Т Б Сенцова,
M P Phabrika
Publication year - 2009
Publication title -
russian journal of allergy
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja901
Subject(s) - atopic dermatitis , medicine , levocetirizine , scorad , antihistamine , dermatology , immunology , disease , dermatology life quality index , pharmacology
Objective. Determination of the role of neuropeptides and p-endorphin in developmental mechanisms ofatopic dermatitis, and assessment of the effectiveness of levocetirizine, a modern Hl-antihistamine, on atopicdermatitis symptoms and its influence on the SCORAD index in children with atopic dermatitis.Materials and methods. 84 children with atopic dermatitis of moderate-to-severe or severe clinical nature,aged 1 to 17 years, were enrolled in this (double-blind or open, randomised, etc.) study. Patients were treatedwith levocetirizine 5 mg once daily during 14 days. The levels of P substance, neurokinin A, neurokinin B,and p-endorphin in blood serum, as well as levocetirizine effectiveness on disease symptoms and the SCORADindex were evaluated.Results. Lower neuropeptide levels were associated with disease severity; children with severe atopicdermatitis had lower neuropeptide values. Before treatment, SCORAD index in children with severe atopicdermatitis was 76,5±11,3, and after 7 days of therapy SCORAD index was 14±6,2 points (p< 0,01). By the 7thday after treatment initiation, the acute atopic dermatitis became of subacute nature and was accompaniedby a regression of the cutaneous eruption in the form of significant decreasing of skin manifestations andpruritus, absence of new eruption and normalized sleep.In children with moderate-to-severe atopic dermatitis the SCORAD index before levocetirizine treatmentwas 44,2±3,4 points; on the 3rd day, this index was 20,4±2,6 points; and on the 7th day there was a completeabsence of clinical symptoms of the main disease.Levocetirizine administration led to the disappearance of the disease clinical symptoms and pruritus inchildren with moderate-to-severe atopic dermatitis.Conclusion. This trial demonstrated that neuropeptides are involved in the developmental mechanisms ofatopic dermatitis and that levocetirizine can significantly improve the signs and symptoms of children withmoderate-to-severe or severe atopic dermatitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom